Top-Rated StocksTop-RatedNASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free ITCI Stock Alerts $68.80 -1.54 (-2.19%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$68.48▼$71.3550-Day Range$64.37▼$79.8452-Week Range$45.50▼$84.89Volume892,882 shsAverage Volume933,643 shsMarket Capitalization$6.66 billionP/E RatioN/ADividend YieldN/APrice Target$90.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Intra-Cellular Therapies alerts: Email Address Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside31.1% Upside$90.17 Price TargetShort InterestHealthy3.71% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.79Based on 5 Articles This WeekInsider TradingSelling Shares$11.36 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.59) to $0.90 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.80 out of 5 starsMedical Sector289th out of 5,430 stocksPharmaceutical Preparations Industry67th out of 2,526 stocks 4.5 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.71% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intra-Cellular Therapies has recently increased by 3.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 3.8 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Intra-Cellular Therapies this week, compared to 4 articles on an average week.Search Interest6 people have searched for ITCI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows48 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,364,950.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.59) to $0.90 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -47.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -47.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 11.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldCould Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesApril 30, 2024 | globenewswire.comIntra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and WebcastApril 27, 2024 | americanbankingnews.comCantor Fitzgerald Research Analysts Raise Earnings Estimates for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)May 4, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 26, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Rating Reiterated by Cantor FitzgeraldApril 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)April 24, 2024 | finance.yahoo.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesApril 24, 2024 | globenewswire.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesApril 24, 2024 | investorplace.com3 Biotech Stocks With Skyrocketing Potential: April 2024May 4, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 24, 2024 | americanbankingnews.comIntra-Cellular Therapies (NASDAQ:ITCI) Given New $107.00 Price Target at Canaccord Genuity GroupApril 22, 2024 | msn.comIpsen, Skyhawk enter RNA targeting research collab in rare neurological diseasesApril 20, 2024 | money.usnews.comIntra-Cellular Therapies IncApril 17, 2024 | globenewswire.comIntra-Cellular Therapies Prices Public Offering of Common StockApril 17, 2024 | investors.comBiotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy PointApril 17, 2024 | finance.yahoo.comIntra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?April 17, 2024 | investing.comBofA ups Intra-Cellular Therapies shares target, buoyed by positive Caplyta trial resultsApril 16, 2024 | markets.businessinsider.comIntra-Cellular Therapies: Hold Rating with Increased Price Target Amid Caplyta’s Clinical SuccessApril 16, 2024 | globenewswire.comIntra-Cellular Therapies Announces Proposed Public Offering of Common StockApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Intra-Cellular Therapies (ITCI)April 16, 2024 | msn.comIntra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment StudyApril 16, 2024 | finance.yahoo.comIntra-Cellular Launches 26% To Record High, Breaking Out After Depression Drug Scores BigApril 16, 2024 | seekingalpha.comIntra-Cellular: More Upside Possible Even After Positive MDD Treatment DataApril 16, 2024 | marketwatch.comIntra-Cellular Therapies Discloses Positive Study Results for Depression TreatmentApril 16, 2024 | marketwatch.comIntra-Cellular Therapies Shares Rise on Lumateperone Study ResultsApril 16, 2024 | markets.businessinsider.comWhy Intra-Cellular Therapies Is Rising In Pre-market?April 16, 2024 | finance.yahoo.comIntra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test ResultsApril 16, 2024 | globenewswire.comIntra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderSee More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/03/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$90.17 High Stock Price Target$120.00 Low Stock Price Target$62.00 Potential Upside/Downside+31.1%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-30.08% Pretax Margin-29.94% Return on Equity-23.02% Return on Assets-19.39% Debt Debt-to-Equity RatioN/A Current Ratio5.41 Quick Ratio5.31 Sales & Book Value Annual Sales$462.18 million Price / Sales14.41 Cash FlowN/A Price / Cash FlowN/A Book Value$6.15 per share Price / Book11.19Miscellaneous Outstanding Shares96,807,000Free Float93,516,000Market Cap$6.66 billion OptionableOptionable Beta1.01 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Comp: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANCytokineticsNASDAQ:CYTKCerevel TherapeuticsNASDAQ:CEREIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsCentral Pacific Bank Trust DivisionBought 3,350 shares on 5/3/2024Ownership: 0.003%Essex Investment Management Co. LLCSold 496 shares on 5/3/2024Ownership: 0.001%Mutual of America Capital Management LLCSold 3,771 shares on 5/2/2024Ownership: 0.048%Jennison Associates LLCBought 9,212 shares on 5/2/2024Ownership: 0.010%Fidelis Capital Partners LLCBought 762 shares on 5/2/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price target for 2024? 10 Wall Street analysts have issued 1-year price objectives for Intra-Cellular Therapies' stock. Their ITCI share price targets range from $62.00 to $120.00. On average, they anticipate the company's share price to reach $90.17 in the next year. This suggests a possible upside of 31.1% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2024? Intra-Cellular Therapies' stock was trading at $71.62 at the beginning of 2024. Since then, ITCI stock has decreased by 3.9% and is now trading at $68.80. View the best growth stocks for 2024 here. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ITCI earnings forecast. How can I listen to Intra-Cellular Therapies' earnings call? Intra-Cellular Therapies will be holding an earnings conference call on Tuesday, May 7th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14. The biopharmaceutical company earned $132.10 million during the quarter, compared to analysts' expectations of $135.97 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 23.02% and a negative net margin of 30.08%. The firm's quarterly revenue was up 50.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.45) earnings per share. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares U.S. Pharmaceuticals ETF (IHE), Invesco Biotechnology & Genome ETF (PBE) and Virtus LifeSci Biotech Products ETF (BBP). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (3.98%), Assenagon Asset Management S.A. (0.67%), Principal Financial Group Inc. (0.54%), Pinnacle Associates Ltd. (0.18%), Raymond James & Associates (0.16%) and Privium Fund Management B.V. (0.11%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ITCI) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry4 Cryptos BETTER than BitcoinTrue Market InsidersThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.